[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621982":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":50,"collaborators":25,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":25,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":25,"enrollmentInfo":62,"targetDuration":25,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":25,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Seoul National University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TCI","EXPERIMENTAL","Remimazolam administered via TCI (target Ce 0.7 μg\u002FmL)",[13],"Other: Target-Controlled Infusion (TCI) of Remimazolam",{"label":15,"type":16,"description":17,"interventionNames":18},"Manual Infusion","ACTIVE_COMPARATOR","Remimazolam administered via manual infusion (6 mg\u002Fkg\u002Fhr for induction, 1-2 mg\u002Fkg\u002Fhr for maintenance)",[19],"Other: Manual Infusion of Remimazolam",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Target-Controlled Infusion (TCI) of Remimazolam","Remimazolam is administered using a target-controlled infusion (TCI) pump based on the Schuttler pharmacokinetic model. The initial target effect-site concentration (Ce) is set at 0.7 μg\u002FmL and adjusted in 0.1 μg\u002FmL increments to maintain a depth of anesthesia between Patient State Index (PSi) 25 and 50.",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Manual Infusion of Remimazolam","Remimazolam is administered via traditional manual weight-based infusion. For anesthesia induction, a rate of 6 mg\u002Fkg\u002Fhr is used. For maintenance, the infusion rate starts at 1 mg\u002Fkg\u002Fhr and is adjusted in 0.2 mg\u002Fkg\u002Fhr increments to maintain a PSi between 25 and 50.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Chang-Hoon Koo","CONTACT","+82317877512","vollock9@gmail.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":25,"cosmosGeoPoint":44,"geoPoint":49,"contacts":25},"Seoul National University Bundang Hospital","RECRUITING","Seongnam-si","Gyeonggi-do","13620","South Korea",{"type":45,"coordinates":46},"Point",[47,48],127.13778,37.43861,{"lat":48,"lon":47},{"type":51,"investigatorFullName":32,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Associate professor","100621982","remimazolam-consumption-tci-vs-manual-infusion-100621982",false,"NCT07377695","Remimazolam Consumption: TCI vs. Manual Infusion","Comparison of Remimazolam Consumption According to Administration Method in Patients Undergoing Cerebrovascular Bypass Surgery: A Prospective Randomized Trial","Inclusion Criteria:\n\n* Patients scheduled to undergo cerebrovascular bypass surgery under general anesthesia.\n* American Society of Anesthesiologists (ASA) Physical Status 1, 2, or 3\n* Adults aged 19 years or older\n* Patients who have provided prior written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients who do not consent to participate in the research\n* Patients classified as ASA Physical Status 4\n* Patients with a BMI ≤18.5 kg\u002Fm2 or 35.0 ≥ kg\u002Fm2\n* History of allergy to benzodiazepine-class medications\n* Patients with acute narrow-angle glaucoma\n* Patients in a state of shock or coma\n* Acute alcohol intoxication with suppressed vital signs , or patients with alcohol or drug dependency\n* Presence of Sleep Apnea Syndrome or severe\u002Facute respiratory failure\n* Patients with lactose intolerance or hypersensitivity to Dextran 40","ALL","19 Years",{"count":63,"type":64},58,"ESTIMATED","INTERVENTIONAL",[67],"NA","The purpose of this prospective randomized controlled trial is to compare the total consumption of remimazolam between two different administration methods-Target-Controlled Infusion (TCI) and manual infusion-in patients undergoing cerebrovascular bypass surgery.",[70],"Moyamoya Disease","2026-04-22",{"date":73,"type":74},"2026-04-23","ACTUAL",{"date":76,"type":74},"2026-02-04",{"date":78,"type":64},"2030-12-31",{"name":5,"class":6},1]